Cara Therapeutics, Inc. Analysis
| Analyst Ratings |
|
Average Target Price
|
23.63
|
|
Average Rating
|
4.25
|
|
# Strong Buys
|
3
|
|
# Buys
|
4
|
|
# Holds
|
1
|
|
# Sells
|
0
|
|
# Strong Sells
|
0
|
| Quarterly Earnings History |
| Quarter |
EPS Estimate |
EPS Actual |
EPS Difference |
Surprise Percent |
|
2022-09-30
|
-0.42
|
-0.43
|
-0.01
|
-2.38%
|
|
2022-06-30
|
-0.25
|
-0.08
|
0.17
|
68.00%
|
|
2022-03-31
|
-0.54
|
-0.52
|
0.02
|
3.70%
|
|
2021-12-31
|
-0.52
|
-0.63
|
-0.11
|
-21.15%
|
|
2021-09-30
|
-0.40
|
-0.02
|
0.38
|
95.00%
|
|
2021-06-30
|
-0.53
|
-0.61
|
-0.08
|
-15.09%
|
|
2021-03-31
|
-0.59
|
-0.47
|
0.12
|
20.34%
|
|
2020-12-31
|
0.36
|
1.59
|
1.23
|
341.67%
|
| Annual Earnings History |
| Fiscal Year End |
EPS |
|
2022-12-31
|
-1.03
|
|
2021-12-31
|
-1.73
|
|
2020-12-31
|
0.08
|
|
2019-12-31
|
-2.49
|
|
2018-12-31
|
-2.06
|
|
2017-12-31
|
-1.91
|
|
2016-12-31
|
-2.10
|
|
2015-12-31
|
-1.00
|
|
2014-12-31
|
-0.85
|
|
2013-12-31
|
-0.49
|